Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Rhea-AI Summary
Cartesian Therapeutics (NASDAQ: RNAC), a late clinical-stage biotech developing cell therapies for autoimmune diseases, will join a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 3:00 p.m. ET. A live and archived webcast will be available on its website.
Positive
- None.
Negative
- None.
News Market Reaction – RNAC
In the May 12 session, RNAC gained 1.99%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Inducement option grants | Neutral | +11.4% | New employees received 317,200 options at a $6.22 exercise price. |
| Apr 30 | Q1 2026 earnings | Positive | -3.9% | Reported $120.4M cash, ATM proceeds, and multiple advancing clinical trials. |
| Apr 02 | Inducement option grants | Neutral | -2.0% | Granted 52,450 options at $6.39 to two new employees. |
| Mar 09 | FY 2025 results | Positive | +31.7% | Announced $126.9M cash, runway into mid-2027, and trial progress. |
| Feb 23 | Conference participation | Neutral | +0.7% | Planned presentations at TD Cowen, Leerink, and Needham investor events. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions have been mixed, with 3 aligned and 2 divergent moves relative to the news tone.
Over the last few months, Cartesian reported full-year 2025 results with $126.9M cash and ongoing Phase 3 AURORA enrollment, followed by Q1 2026 results showing $120.4M cash and continued clinical progress. The company has periodically granted employment inducement options and highlighted participation in multiple investor conferences. Against this backdrop, today’s announcement of another investor conference appearance continues a pattern of active investor outreach alongside advancement of the Descartes-08 clinical program.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, at 3:00 p.m. ET.
A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
